secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2023-04-17T23:59:59+00:00
Accession:  0001193125-23-103787
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia appoints Bill Chase to board; Caroline Dorsa to retire June 15, 2023
-----------------------------------------------------------------------------

- Bill Chase, former AbbVie CFO, appointed as Class III director, effective April 14, 2023.
- Caroline Dorsa to retire from board on June 15, 2023, after being appointed chair of Biogen's board.
- Chase will serve on audit committee and succeed Dorsa as audit committee chair.
- Chase received grant of 14,931 stock options and 10,483 RSUs under director compensation program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312523103787/0001193125-23-103787-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312523103787/d485270d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-103787

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer